BERRY GENOMICS(SZ:000710) Xin Lang Cai Jing·2025-04-28 01:46Core Insights - Berry Genomics (000710.SZ) reported a total revenue of 218 million yuan for Q1 2025, ranking 18th among disclosed peers, which represents a decrease of 61.72 million yuan or 22.08% year-on-year [1] - The company recorded a net profit attributable to shareholders of -6.46 million yuan, ranking 23rd among peers, a decline of 14.70 million yuan or 178.47% compared to the same period last year [1] - Operating cash flow was -34.59 million yuan, placing the company 27th among peers [1] Financial Ratios - The latest debt-to-asset ratio is 29.63%, ranking 19th among peers, an increase of 1.56 percentage points from the previous quarter and 0.17 percentage points from the same period last year [3] - The latest gross profit margin is 49.48%, down 5.57 percentage points year-on-year [3] - Return on equity (ROE) stands at -0.39%, ranking 23rd among peers, a decrease of 0.83 percentage points from the previous year [3] - The diluted earnings per share is -0.02 yuan, ranking 24th among peers, a drop of 0.04 yuan or 200.00% year-on-year [3] - Total asset turnover is 0.09 times, ranking 19th among peers, a decrease of 0.01 times or 11.78% year-on-year [3] - Inventory turnover is 0.57 times, ranking 24th among peers, a decline of 0.01 times or 1.14% year-on-year [3] Shareholder Structure - The number of shareholders is 63,800, with the top ten shareholders holding 133 million shares, accounting for 37.53% of the total share capital [3] - The largest shareholder is Chengdu Tianxing Instrument (Group) Co., Ltd. with a holding of 12.45% [3] - Other significant shareholders include Gao Yang (9.05%), Hongling Siqi (8.49%), and Hou Ying (4.22%) [3]